Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453586 | 1.00 | HSPA5 (0.33) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12243182 | 1.00 | HSPA5 (0.33) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12393231 | 0.92 | HSPA5 (0.33) | HSPA5PDE2A | |
| SCHEMBL19997438 | 0.88 | HSPA5 (0.34) | HSPA5TNK2PDE2A | |
| SCHEMBL12393217 | 0.88 | HSPA5 (0.35) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL19088037 | 0.86 | HSPA5 (0.36) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12393393 | 0.86 | HSPA5 (0.36) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL10082719 | 0.86 | HSPA5 (0.36) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12393386 | 0.85 | HSPA5 (0.35) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12243189 | 0.84 | TNK2 (0.33) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012012465-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | CLARKE, MICHAEL, O'NEIL HANRAHAN (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011150288-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354425-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | HSPA5 344/4885TNK2 2448/4885PDE2A 789/4885 |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | HSPA5 4044/4885TNK2 1269/4885PDE2A 2226/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | HSPA5 2596/4885TNK2 1494/4885PDE2A 2899/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | HSPA5 344/4885TNK2 2448/4885PDE2A 789/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | HSPA5 344/4885TNK2 2448/4885PDE2A 789/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | HSPA5 344/4885TNK2 2448/4885PDE2A 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.